Deutsches Referenzzentrum für Ethik in den Biowissenschaften (DRZE)

Titel: Paving the way for personalized medicine. Legal, ethical and social challenges

Beginn: 18.11.2019, 10:00 -17:00 Uhr

Veranstaltungsort:
University of Salerno
School of Law
Italy

Referenten: Keynote speaker: Professor Leonard M. Fleck (Acting Director Department of Philosophy, Center for Ethics and Humanities in the Life Sciences, Michigan State University (USA)

Weitere Informationen:
https://www.eur.nl/esl/evenementen/paving-way-personalized-medicine-20 ...

Kurzbeschreibung: Personalized medicine (PM) is one of the promising technologies in medicine aimed at developing targeted diagnostics and therapies in “the war on cancer” and other life-threatening diseases. Personalized or precision medicine has been generally justified by finding the right treatments, at the right dose, at the right time for the right person, every time, and simultaneously, increasing the efficiency of health care systems by predicting and treating individual predispositions to diseases or conditions.
In the age of genomic medicine we can now do the genetic testing that will permit more accurate personal tailoring of medications to obtain the best therapeutic results.
Although nobody could be opposed to precision medicine, it generates numerous questions and concerns either in terms of ethics, human rights, financing and other perspectives, addressing:
• What progress has been made so far bringing PM technologies to the market?
• How to overcome clinical trials challenges with PM?
• Is there any evidence of more efficiency in health care by introducing PM approaches?
• Are we morally obligated to implement PM innovations?
• What are the regulatory barriers to PM developments?
• What is the influence of patent law on PM innovations?
• PM and processing genomic data, what are the GDPR risks?
• Who can access such (expensive) technologies, and based on what criteria?
• What will be the impact on national health budgets/ social insurance schemes (de)listing precision medicine therapies, or do we have to make hard choices?
• What are the solutions to identified concerns?
• What is the future of PM in European health care systems?

Kontakt: Stefania Negri
snegri@unisa.it

Artikelaktionen